Novel dipeptide prodrugs of acyclovir for ocular herpes infections: Bioreversion, antiviral activity and transport across rabbit cornea

References

• Green MT, Dunkel E. Herpes Simplex Virus Infections. Philadelphia, PA: Lea and Febiger; 1985.
   Google Scholar
• Easty DL. Clinical Aspects of Ocular Herpes Simplex Virus Infection. Chicago Year Book Medical Publishers; 1985.
   Google Scholar
• Richards DM, Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS. Acyclovir: A review of its phar-macodynamic properties and therapeutic efficacy. Drugs. 1983;26:378–438.
   PubMed Web of Science ®Google Scholar
• Sanitato JJ, Asbell PA, Varnell ED, Kissling GE, Kaufman HE. Acyclovir in the treatment of herpetic stromal disease. Am J Ophthalmol. 1984;98:537–547.
   Google Scholar
• Hughes PM, Mitra AK. Effect of acylation on the ocular disposition of acyclovir. II: Corneal permeability and anti-HSV 1 activity of 2'-esters in rabbit epithelial keratitis. J Ocul Pharmacol. 1993;9: 299–309.
   Google Scholar
• Hughes PM, Krishriamoorthy R, Mitra AK. Effect of acy-lation on the ocular disposition of acyclovir. I: Synthesis, physicochemical properties, and antiviral activity of 2'-esters. J Ocul Pharmacol. 1993;9: 287–297.
   Google Scholar
• Lupia RH, Ferencz N, Lertora JJ, Aggarwal SK, George WJ, Agrawal KC. Comparative pharmacokinetics of two pro-drugs of zidovudine in rabbits: Enhanced levels of zidovu-dine in brain tissue. Antimicrob Agents Chemother. 1993;37:818–824.
   PubMed Web of Science ®Google Scholar
• Weller S, Blum MR, Doucette M, Burnette T, Cederberg DM, de Miranda P, Smiley ML. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther. 1993;54:595–605.
   Google Scholar
• Beauchamp LM, Orr GF, Miranda PD, Krenitsky TA. Amino Acid Ester prodrugs of Acyclovir. Antiviral Chem Chemotherap. 1992;3:157–164.
   Web of Science ®Google Scholar
• Han HK, Oh DM, Amidon GL. Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter. Pharm Res. 1998;15: 1382–1386.
   Google Scholar
• Balimane P, Sinko P Effect of ionization on the variable uptake of valacyclovir via the human intestinal peptide transporter (hPepT1) in CHO cells. Biopharm Drug Dispos. 2000;21:165–174.
   PubMed Web of Science ®Google Scholar
• de Vrueh RL, Smith PL, Lee CP Transport of L-valine-acy-clovir via the oligopeptide transporter in the human intesti-nal cell line, Caco-2. J Pharmacol Exp Ther. 1998; 286:1166–1170.
   PubMed Web of Science ®Google Scholar
• Zhou X, Thamotharan M, Gangopadhyay A, Serdikoff C, Adibi SA. Characterization of an oligopeptide transporter in renal lysosomes. Biochim Biophys Acta. 2000;1466: 372–378.
   PubMed Web of Science ®Google Scholar
• Saito H, Okuda M, Terada T, Sasaki S, Inui K. Cloning and characterization of a rat H+/peptide cotransporter mediat- ing absorption of beta-lactam antibiotics in the intestine and kidney. J Pharmacol Exp Ther. 1995;275:1631–1637.
   Google Scholar
• Lee VH. Membrane transporters. Eur J Pharm Sci. 2000;11 Suppl 2:S41–S50.
   Google Scholar
• Tsuji A, Tamai I. Carrier-mediated intestinal transport of drugs. Pharm Res. 1996;13:963–977.
   PubMed Web of Science ®Google Scholar
• Tamai I, Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci. 2000;89:1371–1388.
   PubMed Web of Science ®Google Scholar
• Oh DM, Han HK, Amidon GL. Drug transport and target-ing: Intestinal transport. Pharm BiotechnoL 1999;12:59–88.
   Google Scholar
• Anand BS, Mitra AK. Mechanism of corneal permeation of L-valyl ester of acyclovir: Targeting the oligopeptide trans-porter on the rabbit cornea. Pharm Res. 2002;19:1194–1202.
   PubMed Web of Science ®Google Scholar
• Anand BS, Patel J, Mitra AK. Interactions of the dipeptide prodrugs of acyclovir with the intestinal oligopeptide trans-porter: Competitive inhibition of glycylsarcosine transport in human intestinal cell line. Journal of Pharmacology and Experimental Therapeutics. 2002 in press.
   Google Scholar
• Izawa K, Shiragami H. Pure Appl Chem. 1998;70.
   PubMed Web of Science ®Google Scholar
• Shiragami K, Koguchi Y, Tanaka Y, Takamatsu S, Uchida Y, Ineyama T, Izawa K. Nucleosides Nucleotides. 1995;14.
   Google Scholar
• Dantzig AH, Bergin L. Uptake of the cephalosporin, cephalexin, by a dipeptide transport carrier in the human intestinal cell line, Caco-2. Biochim Biophys Acta. 1990;1027:211–217.
   PubMed Web of Science ®Google Scholar
• Hashimoto N, Fujioka T, Toyoda T, Muranushi N, Hirano K. Renin inhibitor: Transport mechanism in rat small intestinal brush-border membrane vesicles. Pharm Res. 1994;11:1448–1451.
   Google Scholar
• Kiss A, Farah K, Kim J, Garriock RI, Drysdale TA, Hammond JR. Molecular cloning and functional character-ization of inhibitor-sensitive (mENT1) and inhibitor-resistant (mENT2) equilibrative nucleoside transporters from mouse brain. Biochem J 2000;352 Pt 2:363–372.
   PubMed Web of Science ®Google Scholar
• Han H, de Vrueh RL, Rhie JK, Covitz KM, Smith PL, Lee CP, Oh DM, Sadee W, Amidon GL. 5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res. 1998;15:1154–1159.
   PubMed Web of Science ®Google Scholar
• Inui K, Yamamoto M, Saito H. Transepithelial transport of oral cephalosporins by monolayers of intestinal epithelial cell line Caco-2: Specific transport systems in apical and basolateral membranes. J Pharmacol Exp Ther. 1992; 261:195–201.
   Google Scholar
• Temple CS, Stewart AK, Meredith D, Lister NA, Morgan KM, Collier ID, Vaughan-Jones RD, Boyd CA, Bailey PD, Bronk JR. Peptide mimics as substrates for the intestinal peptide transporter. J Biol Chem. 1998;273:20–22.
   Google Scholar
• Doring F, Will J, Amasheh S, Clauss W, Ahlbrecht H, Daniel H. Minimal molecular determinants of substrates for recog-nition by the intestinal peptide transporter. J Biol Chem. 1998;273:23211–23218.
   PubMed Web of Science ®Google Scholar
• Anand BS, Mitra AK. Mechanism of corneal permeation of L-Valyl ester of acyclovir: Targeting the oligopeptide transporter on the rabbit cornea. Pharmaceutical Research. 2002;19:1194–1202.
   PubMed Web of Science ®Google Scholar
• Fleming DT, McQuillan GM, Johnson RE, Nahmias AJ, Aral SO, Lee FK, St Louis ME. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med. 1997;337: 1105–1111.
   Google Scholar
• Hughes PM, Krishriamoorthy R, Mitra AK. Effect of acy-lation on the ocular disposition of acyclovir. I: Synthesis, physicochemical properties, and antiviral activity of 2'-esters. J Ocul Pharmacol. 1993;9: 287–297.
   Google Scholar
• Stratford RE, Jr, Lee VH. Ocular aminopeptidase activity and distribution in the albino rabbit. Curr Eye Res. 1985;4:995–999.
   Google Scholar
• Guo A, Hu P, Balimane PV, Leibach FH, Sinko PJ. Inter-actions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J Pharmacol Exp Ther. 1999;289: 448–454.
   Google Scholar
• Sinko PJ, Balimane PV. Carrier-mediated intestinal absorp-tion of valacyclovir, the L-valyl ester prodrug of acyclovir: 1. Interactions with peptides, organic anions and organic cations in rats. Biopharm Drug Dispos. 1998;19:209–217.
   Google Scholar